title: Leukemic cells with 11q23 translocations express granulocyte colony-stimulating factor (G-CSF) receptor and their proliferation is stimulated with G-CSF.
abstract: We report a 20-month-old boy with acute lymphoblastic leukemia with the 11q23 translocation whose blasts markedly increased in peripheral blood after intravenous granulocyte colony-stimulating factor (G-CSF) administration, but disappeared after stopping G-CSF. The in vitro study showed that the leukemic cells separated from this patient expressed G-CSF receptor (G-CSFR) and an addition of G-CSF stimulated their proliferation by 3H-thymidine incorporation assay (stimulation index, 4.9). To clarify whether or not leukemic cells with 11q23 translocations generally express G-CSFR and show proliferative response to G-CSF, we performed the similar in vitro experiments using eight leukemic cell lines with 11q23 translocations. We found that all cell lines examined expressed G-CSFR (20-98%) and proliferation of seven leukemic cell lines was significantly enhanced in response to G-CSF (stimulation index >1.5 in five cell lines), suggesting a possible participation of the G-CSF/G-CSFR interaction in the process of growth regulation of leukemic cells with 11q23 translocations.
authors.affiliation: Department of Pediatrics, Yamanashi Medical University, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Inukai
authors.forename: K
authors.initials: K
authors.lastname: Sugita
authors.forename: K
authors.initials: K
authors.lastname: Iijima
authors.forename: K
authors.initials: K
authors.lastname: Goi
authors.forename: T
authors.initials: T
authors.lastname: Tezuka
authors.forename: S
authors.initials: S
authors.lastname: Kojika
authors.forename: K
authors.initials: K
authors.lastname: Kagami
authors.forename: T
authors.initials: T
authors.lastname: Mori
authors.forename: A
authors.initials: A
authors.lastname: Kinoshita
authors.forename: T
authors.initials: T
authors.lastname: Suzuki
authors.forename: T
authors.initials: T
authors.lastname: O-Koyama
authors.forename: S
authors.initials: S
authors.lastname: Nakazawa
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000187:drug effects / Q000473:pathology; D001752:Blast Crisis; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002874:Chromosome Mapping; D002880:Chromosomes, Human, Pair 11; D003561:Cytarabine / Q000008:administration & dosage; D004261:DNA Replication / Q000187:drug effects; D005047:Etoposide / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use*; D006098:Granulocytes / Q000187:drug effects / Q000473:pathology; D006801:Humans; D016130:Immunophenotyping; D007223:Infant; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D016188:Receptors, Granulocyte Colony-Stimulating Factor / Q000096:biosynthesis* / Q000097:blood; D014407:Tumor Cells, Cultured
chemical_list: D016188:Receptors, Granulocyte Colony-Stimulating Factor; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D008942:Mitoxantrone